ReviewFrontiers in immunology2024

Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.

Xin Fei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.